

## Confirmed Speakers

### KEYNOTE LECTURE

#### Molecular Recognition in Protein-Ligand Complexes



Prof. Gerhard KLEBE  
(PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany)

### INVITED LECTURES

#### SESSION 1: Method Development & Emerging Technologies

##### No Crystal, No Problem: Hydrogen Deuterium Exchange Mass Spectrometry in Drug Discovery



Dr Nino CAMPOBASSO  
(GLAXOSMITHKLINE, Collegeville, United States)

##### Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay



Dr Pär NORDLUND  
(KAROLINSKA INSTITUTE & NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore)

##### Second-Harmonic Generation (SHG) Measures and Resolves Protein Conformations: High-Throughput Structural Drug Discovery



Dr Joshua SALAFSKY  
(BIODESY, South San Francisco, United States)

#### SESSION 2: Biophysics for Integral Membrane Proteins

##### Fluorine NMR Screening: Principles and Application to a Membrane Protein



Dr Claudio DALVIT  
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

##### Improving the Biophysical Properties of GPCRs for Drug Screening and Structural Biology



Prof. Andreas PLÜCKTHUN  
(UNIVERSITY OF ZÜRICH, Zurich, Switzerland)

#### SESSION 3: Impact of Biophysics on Drug Discovery Projects

##### Biophysical Approaches for Hit Finding and Evaluation at Bayer



Dr Ursula EGNER  
(BAYER, Berlin, Germany)

##### Making Every Interaction Count: Impact of Biophysical Methods Across the AstraZeneca Small-Molecule Portfolio

## Confirmed Speakers



Dr Stefan GESCHWINDNER  
(ASTRAZENECA, Mölndal, Sweden)

### Some Examples of Biophysics Helping Drug Discovery



Prof. Rod HUBBARD  
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)

### Biophysics and Structural Biology Enabling the Discovery of Therapeutic Solutions: from Small Molecule Inhibitors to Vaccine Design



Dr Vincent MIKOL  
(SANOFI, Vitry-sur-Seine, France)

## SESSION 4: The Use of Kinetics in Drug Discovery

### CCR2 Antagonists: From Structure-Kinetics Relationships to in vivo Efficacy



Prof. Laura HEITMAN  
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

### Towards a Better Understanding of the Structural Mechanisms of Kinase Inhibitor Binding Kinetics



Prof. Stefan KNAPP  
(OXFORD UNIVERSITY, Oxford, United Kingdom)

### Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure



Dr Herbert NAR  
(BOEHRINGER INGELHEIM, Biberach, Germany)

## SESSION 5: Special Focus on Epigenetics

### When to get Biophysical with Readers, Writers and Erasers



Dr Chun-wa CHUNG  
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

### Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics



Dr Robert A. COPELAND  
(EPIZYME, Cambridge, United States)

### Interrogating the Bromodomain Family Through Chemical Biology

## Confirmed Speakers



Dr Richard CUMMINGS  
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

## ORAL COMMUNICATIONS

### Characterization of IL17A Inhibitors by Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS)



Mr Alfonso ESPADA  
(ELI LILLY, MADRID, Spain)

### A Universal Homogeneous Assay for High-Throughput Determination of Binding Kinetics



Dr Amaury FERNANDEZ MONTALVAN  
(BAYER, Biberach an der Riss, Germany)

### Drug Discovery at the Single Molecule Level



Dr Anders GUNNARSSON  
(ASTRAZENECA, Mölndal, Sweden)

### First Crystal Structure of Transmembrane Domain of G-Protein-Coupled Receptor MGLU5 Provides Insight Into Efficient New Drugs Design



Dr Krzysztof OKRASA  
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

### CDK8 Inhibitors with Long Residence Time Emerging from a Retro-Design Approach: New Opportunities for Cancer Treatment



Dr Anita WEGERT  
(MERCACHEM-SYNCOM, Nijmegen, The Netherlands)

### Strategies to Target Protein-Protein Interactions



Dr Marta WESTWOOD  
(UCB, Slough, United Kingdom)